Overview of the Most Significant Drugs in Specialty Pharmacy FDA Pipeline in 2022
May 3rd 2022Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses some of the more significant drugs for specialty pharmacy in the FDA pipeline this year.
Watch
Improved Health Equity, Outcomes Reported With Omidubicel for Patients With Blood Cancers
May 2nd 2022Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.
Read More
FDA Approves Upadacitinib for Active Ankylosing Spondylitis
May 2nd 2022FDA approves 15 mg upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active ankylosing spondylitis who previously showed an inadequate response or intolerance to 1 or more tumor necrosis factor inhibitors.
Read More
FDA Approves Osteseconazole for Recurrent Vulvovaginal Candidiasis
May 2nd 2022Osteseconazole (Vivjoa) is the first FDA-approved treatment for recurrent vulvovaginal candidiasis, also known as chronic yeast infection, in women with a history of the condition who are not of reproductive potential.
Read More